GlaxoSmithKline has increased its share in biopharmaceutical company Theravance, the firm’s development partner of Relovair, a once-daily treatment for asthma and chronic obstructive pulmonary disease (COPD).

Following approval by Theravance stockholders on 15 May 2012, GSK now owns 25.8 million shares, or 26.7% of Theravance common stock.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

GSK initially purchased 10 million shares for $21.29 apiece.

Theravance entered into a long-term agreement with GSK in November 2002 for the development of inhaled corticosteroid (ICS) / LABA combination, Relovair.

The drug, which has now completed its Phase 3 development, is a follow-up of GSK’s blockbuster Advair which expired in September 2010.

GSK intends to submit regulatory applications for Relovair for the treatment of COPD in the US and Europe, in mid-2012.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

For asthma, the firm also plans to submit an application in Europe in mid-2012 and GSK and Theravance are reviewing the strategy for a future US filing.